Literature DB >> 22801104

Endocrine-related cancers and the role of AMPK.

Kristy A Brown1, Nirukshi U Samarajeewa, Evan R Simpson.   

Abstract

AMP-activated protein kinase (AMPK) is a master regulator of energy homeostasis involved in the regulation of a number of physiological processes including β-oxidation of fatty acids, lipogenesis, protein and cholesterol synthesis, as well as cell cycle inhibition and apoptosis. Important changes to these processes are known to occur in cancer due to changes in AMPK activity within cancer cells and in the periphery. This review aims to present findings relating to the role and regulation of AMPK in endocrine-related cancers. Obesity is a known risk factor for many types of cancers and a number of endocrine factors, including adipokines and steroid hormones, are regulated by and regulate AMPK. A clear role for AMPK in breast cancer is evident from the already impressive body of work published to date. However, information pertaining to its role in prostate cancer is still contentious, and future work should unravel the intricacies behind its role to inhibit, in some cases, and stimulate cancer growth in others. This review also presents data relating to the role of AMPK in cancers of the endometrium, ovary and colon, and discusses the possible use of AMPK-activating drugs including metformin for the treatment of all endocrine-related cancers.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22801104     DOI: 10.1016/j.mce.2012.06.016

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  20 in total

Review 1.  Metabolic pathways in obesity-related breast cancer.

Authors:  Kristy A Brown
Journal:  Nat Rev Endocrinol       Date:  2021-04-29       Impact factor: 43.330

Review 2.  AMP-activated protein kinase and energy balance in breast cancer.

Authors:  Hong Zhao; Yelda C Orhan; Xiaoming Zha; Ecem Esencan; Robert T Chatterton; Serdar E Bulun
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

3.  Resveratrol induces AMPK-dependent MDR1 inhibition in colorectal cancer HCT116/L-OHP cells by preventing activation of NF-κB signaling and suppressing cAMP-responsive element transcriptional activity.

Authors:  Ziyuan Wang; Long Zhang; Zhenhua Ni; Jian Sun; Hong Gao; Zhuoan Cheng; Jianhua Xu; Peihao Yin
Journal:  Tumour Biol       Date:  2015-07-01

Review 4.  A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer.

Authors:  Ayesha S Khan; Daniel E Frigo
Journal:  Nat Rev Urol       Date:  2017-02-01       Impact factor: 14.432

5.  Adiposity Results in Metabolic and Inflammation Differences in Premenopausal and Postmenopausal Women Consistent with the Difference in Breast Cancer Risk.

Authors:  H Zhao; J Wang; D Fang; O Lee; R T Chatterton; V Stearns; S A Khan; S E Bulun
Journal:  Horm Cancer       Date:  2018-03-15       Impact factor: 3.869

Review 6.  Dysregulation of RNA polymerase I transcription during disease.

Authors:  K M Hannan; E Sanij; L I Rothblum; R D Hannan; R B Pearson
Journal:  Biochim Biophys Acta       Date:  2012-11-12

7.  Hsp90 and PKM2 Drive the Expression of Aromatase in Li-Fraumeni Syndrome Breast Adipose Stromal Cells.

Authors:  Kotha Subbaramaiah; Kristy A Brown; Heba Zahid; Gabriel Balmus; Robert S Weiss; Brittney-Shea Herbert; Andrew J Dannenberg
Journal:  J Biol Chem       Date:  2016-06-01       Impact factor: 5.157

8.  Klotho rewires cellular metabolism of breast cancer cells through alteration of calcium shuttling and mitochondrial activity.

Authors:  Riva Shmulevich; Tsipi Ben-Kasus Nissim; Ido Wolf; Keren Merenbakh-Lamin; Daniel Fishman; Israel Sekler; Tami Rubinek
Journal:  Oncogene       Date:  2020-05-12       Impact factor: 9.867

Review 9.  Minireview: Obesity and breast cancer: a tale of inflammation and dysregulated metabolism.

Authors:  Evan R Simpson; Kristy A Brown
Journal:  Mol Endocrinol       Date:  2013-03-21

10.  First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer.

Authors:  Filip Janku; Patricia LoRusso; Aaron S Mansfield; Rita Nanda; Alexander Spira; Tianli Wang; Amal Melhem-Bertrandt; Jennifer Sugg; Howard A Ball
Journal:  Invest New Drugs       Date:  2021-04-08       Impact factor: 3.651

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.